Prostate Cancer Screening in Population of Eastern Nepal: A Field Study

Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males, accounting for 14% (903,500) of the total new cancer cases and 6% (258,400) of the total cancer deaths in males in 2008 (Jemal et al, 2011). Descriptive epidemiology has shown wide et...

Full description

Saved in:

Bibliographic Details
Main Author:	Belbase , Dr. Narayan Prasad
Format:	Technical Report
Language:	en_US
Published:	2012
Subjects:	Prostate Cancer Eastern Nepal
Online Access:	http://103.69.126.140:8080/handle/123456789/809
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:103.69.126.140:123456789-809
record_format	dspace
spelling	oai:103.69.126.140:123456789-8092022-11-09T06:50:16Z Prostate Cancer Screening in Population of Eastern Nepal: A Field Study Belbase , Dr. Narayan Prasad Prostate Cancer Eastern Nepal Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males, accounting for 14% (903,500) of the total new cancer cases and 6% (258,400) of the total cancer deaths in males in 2008 (Jemal et al, 2011). Descriptive epidemiology has shown wide ethnic/racial differences in the incidence of Prostate carcinoma. The highest incidence rate group (100/100,000/year) includes African Americans in the United States; intermediate rates (20–50/100,000/year) are observed in Canada, South America, and European countries; and lowest rates (10/100,000/year) in Japan, China, and India (Watanbe et al, 2000). Temporal trends in incidence rates in countries with higher uptake of PSA testing such as the United States, Australia, Canada, and the Nordic countries followed similar patterns (Jemal et al, 2011). Prostate cancer has a highly variable natural history, ranging from an indolent and silent entity throughout a man’s entire life to one that grows rapidly, metastasizing to lymph nodes and bone, with a median life expectancy of 24 to 36 months after bony metastases are detected. It is largely asymptomatic until metastases are present. The medical community has advocated early detection and treatment of prostate cancer for nearly a century. As early as 1905, the noted urologist Hugh H. Young, concluded that careful digital rectal examination (DRE) could identify prostatic changes that herald the first signs of cancer. For the next 75 years, this was the only screening test available, but an imperfect one (Brawley et al, 2009. In the early 1980s, clinicians reacted with optimism to initial studies using a blood protein, prostate–specific antigen (PSA), as a screening test for this disease because of an increasing death rate and the poor performance of the DRE (Catalona et al, 1991). 2012-12-29T05:10:46Z 2022-11-08T10:21:10Z 2012-12-29T05:10:46Z 2022-11-08T10:21:10Z 2010-09 Technical Report http://103.69.126.140:8080/handle/123456789/809 en_US application/pdf
institution	My University
collection	DSpace
language	en_US
topic	Prostate Cancer Eastern Nepal
spellingShingle	Prostate Cancer Eastern Nepal Belbase , Dr. Narayan Prasad Prostate Cancer Screening in Population of Eastern Nepal: A Field Study
description	Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males, accounting for 14% (903,500) of the total new cancer cases and 6% (258,400) of the total cancer deaths in males in 2008 (Jemal et al, 2011). Descriptive epidemiology has shown wide ethnic/racial differences in the incidence of Prostate carcinoma. The highest incidence rate group (100/100,000/year) includes African Americans in the United States; intermediate rates (20–50/100,000/year) are observed in Canada, South America, and European countries; and lowest rates (10/100,000/year) in Japan, China, and India (Watanbe et al, 2000). Temporal trends in incidence rates in countries with higher uptake of PSA testing such as the United States, Australia, Canada, and the Nordic countries followed similar patterns (Jemal et al, 2011). Prostate cancer has a highly variable natural history, ranging from an indolent and silent entity throughout a man’s entire life to one that grows rapidly, metastasizing to lymph nodes and bone, with a median life expectancy of 24 to 36 months after bony metastases are detected. It is largely asymptomatic until metastases are present. The medical community has advocated early detection and treatment of prostate cancer for nearly a century. As early as 1905, the noted urologist Hugh H. Young, concluded that careful digital rectal examination (DRE) could identify prostatic changes that herald the first signs of cancer. For the next 75 years, this was the only screening test available, but an imperfect one (Brawley et al, 2009. In the early 1980s, clinicians reacted with optimism to initial studies using a blood protein, prostate–specific antigen (PSA), as a screening test for this disease because of an increasing death rate and the poor performance of the DRE (Catalona et al, 1991).
format	Technical Report
author	Belbase , Dr. Narayan Prasad
author_facet	Belbase , Dr. Narayan Prasad
author_sort	Belbase , Dr. Narayan Prasad
title	Prostate Cancer Screening in Population of Eastern Nepal: A Field Study
title_short	Prostate Cancer Screening in Population of Eastern Nepal: A Field Study
title_full	Prostate Cancer Screening in Population of Eastern Nepal: A Field Study
title_fullStr	Prostate Cancer Screening in Population of Eastern Nepal: A Field Study
title_full_unstemmed	Prostate Cancer Screening in Population of Eastern Nepal: A Field Study
title_sort	prostate cancer screening in population of eastern nepal: a field study
publishDate	2012
url	http://103.69.126.140:8080/handle/123456789/809
work_keys_str_mv	AT belbasedrnarayanprasad prostatecancerscreeninginpopulationofeasternnepalafieldstudy
_version_	1761501186449473536

Prostate Cancer Screening in Population of Eastern Nepal: A Field Study

Similar Items